What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to disclose the presentation materials from Merck's R&D and Business Briefing held on November 10, 2011. This ensures that information shared with select parties is made available to the public under Regulation FD.

Where can I find the specific information discussed at the briefing?

The detailed information discussed at the R&D and Business Briefing is contained within Exhibit 99.1, which is attached to this 8-K filing. Investors should refer to this exhibit for the content of the presentations.

Does this filing include Merck's latest financial results?

No, this 8-K filing does not include Merck's latest financial results. It is primarily a disclosure of presentation materials and does not contain updated financial statements or significant operational data.

What does 'Regulation FD Disclosure' mean in this context?

Regulation FD (Fair Disclosure) is an SEC rule that requires public companies to make broad and public dissemination of material non-public information about their businesses and financial condition. This filing, by including the presentation materials, complies with that regulation.

MRK 8-K: Regulation FD — Nov 10, 2011

Summary

Merck & Co., Inc. filed an 8-K on November 10, 2011, primarily to disclose materials presented during an R&D and Business Briefing on November 10, 2011. While the filing itself does not contain new financial results or significant operational updates, it serves as a disclosure vehicle for presentations made by senior executive officers. Investors should review the referenced Exhibit 99.1, which contains the actual presentation materials, for detailed insights into the company's research and development pipeline, strategic priorities, and business outlook as articulated by leadership at that time.

Key Highlights

1Disclosure of R&D and Business Briefing materials (Exhibit 99.1).
2Presentations delivered by senior executive officers of Merck & Co., Inc.
3Event date for the briefing was November 9, 2011 (filing date November 10, 2011).
4Information is provided under Regulation FD to ensure broad public dissemination.
5The filing itself does not contain new financial statements or material business updates beyond the presented materials.
6Investors are directed to Exhibit 99.1 for the core content of the disclosure.

Merck & Co., Inc. 8-K Report, Regulation FD Disclosure (Nov 10, 2011)

Summary

Key Highlights

Frequently Asked Questions